查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1863147

全球疼痛管理設備市場：洞察、競爭格局及至2032年預測

Pain Management Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

疼痛管理設備市場摘要

  • 全球疼痛管理設備市場預計將從 2024 年的 52.773 億美元成長到 2032 年的 93.5072 億美元，反映出強勁且持續的成長。
  • 全球疼痛管理設備市場在 2025 年至 2032 年的預測期內將以 7.53% 的複合年成長率成長。
  • 受慢性疼痛盛行率上升、新產品頻繁上市以及人們對疼痛管理解決方案的認知不斷提高的推動，全球疼痛管理設備市場預計將在2025年至2032年間快速成長。對微創設備的需求不斷成長以及相關的宣傳宣傳活動正在推動這些設備的普及，為創新和改善患者療效創造了強勁的機會。
  • 在疼痛管理設備市場中運作的主要企業包括：雅培實驗室、史密斯醫療、貝朗公司、百特國際、波士頓科學公司、Avanos Medical公司、美敦力、Nevro公司、ICU Medical公司、歐姆龍公司、Stimwave LLC、Nipro、O&M Halyard、EndoStim公司、Nalu Medicalyn、Micrelwave、Micrel Medicali​​Y、Danoi​​Y
  • 由於慢性疼痛負擔沉重、意識提升提升、政府支持計劃以及不斷的產品創新和頻繁的 FDA核准，預計北美將繼續保持其在疼痛管理設備市場的主導地位。
  • 根據設備類型分類，預計到 2024 年，疼痛管理設備市場將佔最大的市場佔有率，其中神經刺激設備類別將佔 100% 的市場佔有率。

疼痛管理設備市場成長要素

  • 慢性疼痛及相關疾病的日益普遍促使疼痛管理設備市場迅速擴張：這不是一個單一的孤立因素，而是由多個相互關聯的人口和健康趨勢造成的複雜問題。
  • 人口老化：隨著全球預期壽命的延長，65歲及以上人口的比例不斷增加。這種人口結構變化與慢性疼痛盛行率的上升直接相關。老年人更容易患上與老齡化相關的疾病，這些疾病會導致持續性疼痛，例如：
  • 骨關節炎：骨關節炎：一種隨著老齡化而日益常見的退化性關節疾病。
  • 肌肉骨骼疾病：包括背痛，這是全球造成殘疾的主要原因之一。
  • 神經病變疼痛：老齡化相關的神經損傷引起的神經相關疼痛。
  • 慢性疾病：糖尿病和癌症等慢性疾病在全球造成的負擔日益加重，促使神經病變疼痛和其他需要長期治療的疼痛形式日益普遍。
  • 糖尿病：糖尿病會導致一種稱為糖尿病性神經病變的神經病變，進而引起慢性疼痛、麻木和癱瘓。
  • 癌症：疾病本身及其治療（化療、放射線治療等）都會引起劇烈且持續的疼痛。
  • 肥胖：會對關節和骨骼系統造成壓力，增加背部、膝蓋和髖部疼痛的發生率。
  • 生活方式的改變：久坐的生活方式和職業因素導致腰痛和其他肌肉骨骼問題等疾病的增加，從而刺激了對非藥物止痛的需求。
  • 久坐的生活方式：長時間坐在文書工作或螢幕前會導致姿勢不良和慢性背部和頸部疼痛。
  • 重複性勞損會導致腕隧道症候群和其他肌腱炎等疾病。
  • 擺脫鴉片類藥物鎮痛：這是推動鎮痛設備市場成長的關鍵因素，也是對全球公共衛生危機的直接回應。
  • 鴉片類藥物危機及其影響：全球鴉片類藥物危機凸顯了傳統止痛藥成癮、誤用和濫用的風險。這促使醫療專業人員、患者和監管機構積極尋求更安全、無成癮性的替代方案。此外，鴉片類鎮痛藥在治療急性和慢性疼痛方面的過度處方已導致許多國家，特別是美國，出現公共衛生危機。主要問題包括：
  • 成癮與濫用：許多因疼痛管理而服用鴉片類藥物的人會發展出成癮和依賴性，這可能導致物質使用障礙，在某些情況下，還會導致更危險的非法鴉片類藥物，如海洛因或Fentanyl。
  • 過量用藥致死：處方藥和非法鴉片類藥物導致的過量用藥致死現象十分普遍，是意外傷害致死的主要原因。
  • 公眾和專家的關注：這場危機的規模引起了公眾、衛生專業人員和政策制定者的廣泛關注，從而強烈推動非藥物替代療法。
  • 減少副作用：疼痛管理設備，尤其是非侵入性設備，提供了一種緩解疼痛的方法，而不會像口服止痛藥那樣產生全身性副作用（如嗜睡、噁心和便秘）。
  • 多模態疼痛管理的興起：減少鴉片類藥物的使用正在加速多模態疼痛管理方法的普及，這種方法結合多種不同的治療方法以達到最佳的疼痛緩解效果。疼痛管理設備完美契合這種模式，因為它們可以與非鴉片類藥物（例如非類固醇抗發炎藥）、物理治療和其他干預措施聯合使用。例如，術後復健患者可以使用經皮神經電刺激（TENS）設備來控制術後疼痛，從而減少對口服鴉片類藥物的需求。

摘要，鴉片類藥物危機猶如一記強勁的催化劑，迫使人們從根本上改變疼痛治療方式。這為疼痛管理設備創造了巨大的市場機遇，這些設備被定位為比傳統藥物鎮痛更安全、無成癮性且更有效的替代方案。

  • 技術進步與創新
  • 神經調控技術：神經刺激技術的突破性進展，包括閉合迴路系統和微型植入式設備，使這些治療方法更有效、更個人化、侵入性更小。
  • 智慧型穿戴裝置：可攜式、使用者友善的穿戴裝置（例如 TENS 裝置）的開發，使得在家中進行疼痛管理更加方便，減少了頻繁就醫的需要。
  • 與數位健康融合：人工智慧 (AI)、遠端監測和數位健康平台的融合將實現更精準、數據主導的疼痛管理，從而改善患者的治療效果。

疼痛管理設備市場報告區隔

本疼痛管理設備市場報告全面概​​述了全球疼痛管理設備市場，重點分析了關鍵趨勢、成長促進因素、挑戰和機會。報告按設備類型、應用、最終用戶和地區對市場進行區隔，深入剖析了北美、歐洲和亞太等主要市場的競爭格局、監管環境和市場動態。報告詳細介紹了行業領導者的概況和最新產品開發情況，為企業提供關鍵數據，幫助其識別市場潛力、制定策略規劃，並在快速成長的疼痛管理設備市場中掌握新機會。

疼痛管理設備是一類旨在緩解疼痛的醫療設備，其作用機制無需口服藥物（尤其是鴉片類藥物）或可作為口服藥物的替代方案。這些醫療設備透過刺激人體自身的疼痛緩解機製或阻斷疼痛訊號傳遞至大腦來發揮作用。它們可用於治療多種慢性及急性疼痛，包括肌肉骨骼疾病、神經病變疼痛以及術後恢復期疼痛。

慢性疼痛盛行率的不斷上升，以及產品上市數量的增加和人們對疼痛管理解決方案認知度的提高，預計將推動全球疼痛管理設備市場顯著成長。患者對有效、微創治療的需求日益成長，加劇了市場競爭和技術創新，主要企業正不斷推出先進設備以拓展治療選擇。此外，宣傳宣傳活動和患者權益倡導也促進了這些技術在全球的普及和應用。預計在2025年至2032年的預測期內，這些因素將改善慢性疼痛患者的治療效果，並提高其生活品質，從而為市場擴張創造有利環境。

全球疼痛管理設備市場正經歷強勁成長，這主要得益於腫瘤、肌肉骨骼和神經系統疾病等慢性疼痛疾病盛行率的不斷上升。尤其是神經性神經病變（NCP），傳統治療方法往往難以有效控制。全球癌症患者數量的快速成長，包括乳癌、肺癌和前列腺癌患者，持續推動對先進疼痛管理解決方案的需求。根據DelveInsight（2024）的數據顯示，2023年七大主要國家的三陰性乳癌（TNBC）病例數約為10.2萬例。 2022年全球乳癌發生率達230萬例，預計2045年將成長至336萬例。不斷擴大的患者群體凸顯了創新設備在有效緩解疼痛和改善患者生活品質方面的重要作用。

根據「全球疾病負擔報告」（2023年版），預計到2050年，骨關節炎將影響近10億人，其中膝關節（成長74.9%）、髖關節（成長78.6%）、手部（成長48.6%）以及其他關節（如肘關節和肩關節，成長95.1%）的患病率成長率最為顯著。這種快速成長凸顯了對便捷有效的鎮痛技術的迫切需求，也表明疼痛管理設備對於應對骨關節炎的長期影響至關重要。

根據發表在「柳葉刀神經病學」的「2021年全球疾病負擔研究」，神經系統疾病影響34億人，佔世界人口的43%，是導致殘疾和健康問題的主要原因之一。緊張性頭痛（約20億例）和偏頭痛（11億例）仍然十分普遍。包括靶向枕神經在內的神經刺激系統已被證明能有效阻斷疼痛訊號，緩解慢性頭痛和偏頭痛。同時，糖尿病性神經病變的盛行率自1990年以來成長了兩倍多，到2021年達到2.06億，這推動了旨在緩解神經相關疼痛的設備得到廣泛應用。

癌症、骨關節炎和神經系統疾病的日益普遍，加上領先企業不斷進行產品創新，為全球疼痛管理設備市場的擴張創造了非常有利的環境。

然而，全球疼痛管理設備市場的成長受到三大主要阻礙因素的顯著阻礙：設備和手術成本高昂、法律規範嚴格複雜，以及植入式設備固有的風險和併發症。高昂的成本構成高成本障礙，因為神經刺激設備等先進設備的製造成本高昂，相關的手術費用對許多患者和醫療系統而言難以承受，而且報銷往往不穩定。此外，法規環境也充滿挑戰。高風險設備冗長且成本高昂的核准流程扼殺了創新，並延緩了新技術進入市場。最後，患者和醫生對手術風險和潛在的設備特異性併發症（例如導線移位和療效隨時間推移而降低）的擔憂限制了他們對設備的接受度。儘管對無鴉片類藥物疼痛管理解決方案的需求日益成長，但這些因素共同構成了重大障礙，阻礙了市場充分發揮其潛力。

在神經刺激設備領域，脊髓刺激設備（SCS）預計將在 2024 年佔神經刺激設備市場 45% 以上的佔有率。這一主導地位主要是由於 SCS 作為治療慢性頑固性疼痛的標準療法在臨床上廣泛應用。

神經刺激設備市場正經歷顯著成長，這主要得益於多種因素的共同作用。慢性疾病（例如慢性疼痛）的全球盛行率不斷上升，日益加重的疾病負擔推動了對有效、長期治療方案的需求。此外，技術的重大進步也使這些設備更加有效且易於使用。小型可充電植入、能夠即時回應神經活動的「封閉回路型」系統以及經顱磁刺激 (TMS) 等非侵入性療法的開發，都在推動這些設備的普及應用。此外，更有利的法規環境和更完善的報銷政策也使患者更容易獲得這些治療。這包括監管機構廣泛核准神經刺激設備的新用途，以及保險公司提供更全面的保險覆蓋。

根據世界衛生組織（WHO）（2023 年）的數據，目前約有 6.19 億人患有腰痛，預計到 2050 年這一數字將達到 8.43 億人。同時，歐洲疼痛聯盟（2023 年）報告稱，全球整體約有 7.4 億人一生中至少會經歷一次劇烈疼痛，近 20% 的人患有持續超過三個月的慢性疼痛。

脊髓刺激設備（SCS）作為治療方法，正日益受到關注。 SCS透過向脊髓刺激設備輸送靶向電脈衝，阻斷疼痛訊號到達大腦，從而顯著改善患者的治療方法品質。

此外，美國國立衛生研究院 (NIH) 於 2023 年發表的一項研究表明，10% 至 40% 的患者在脊椎手術後會患上腰椎手術失敗症候群 (FBSS)。隨著椎間盤突出、椎管狹窄和椎間盤退化性疾病等疾病的脊椎手術數量增加，FBSS 的盛行率也持續上升。由於反覆手術風險高且往往無法提供持久的疼痛緩解，脊椎脊髓刺激設備作為一種有效的替代方案正日益受到認可。脊髓刺激器具有降低鴉片類藥物依賴性、改善功能預後和降低長期醫療保健成本的潛力，使其成為更受歡迎的治療選擇，尤其適用於 FBSS 和慢性神經病變疼痛患者。

2024 年 4 月，美敦力公司獲得 FDA核准推出 Inceptiv™，這是首個閉合迴路SCS 系統，它利用即時生物回饋（誘發複合動作電位，ECAP）自動調節刺激，即使在日常活動中也能保持最佳治療效果。

2023年4月，百多力（Biotronik）的Prospera脊髓刺激系統獲得FDA核准。該系統採用RESONANCE技術，這是首個多相刺激模式；同時還配備了Embrace One系統，這是一種以患者為中心的護理模式，可提供自動化、客觀的日常遠端核准、持續管理和支援。該系統還包括HomeStream遠端系統管理、可充電植入，並相容於全身MRI成像。

這些進步都凸顯了 SCS 市場的發展軌跡，即從需要定期在診所進行調整的傳統固定輸出設備，轉向強調遠端照護、個人化和工作流程效率的智慧自適應系統。

疼痛管理設備市場區域分析

北美疼痛管理設備市場趨勢

在美國的引領下，北美將在2024年佔全球疼痛管理設備市場45%的佔有率。北美疼痛管理設備市場正經歷強勁成長，這主要歸功於三個因素：慢性疼痛負擔日益加重、近期產品創新和核准激增以及政府支持措施。

根據美國疾病管制與預防中心（CDC）的最新數據，預計到2021年，美國將有5,160萬美國（佔總人口的20.9%）患有慢性疼痛。其中，有相當一部分人（1,710萬人）遭受嚴重的慢性疼痛，嚴重影響了他們的日常生活能力。人口老化加劇了這個問題，老年人更容易患上關節炎等慢性疾病。 CDC指出，2022年美國確診關節炎的年齡調整盛行率將達到18.9%，75歲以上族群的盛行率將飆升至53.9%。慢性疼痛的普遍流行使得人們對超越傳統藥物的有效長期疼痛管理方案產生了巨大且持續的需求。

市場成長也得益於近期一系列改變治療方式的產品核准和上市。這些新型設備通常採用微創技術，並融合了人工智慧 (AI) 和閉合迴路系統等先進技術，能夠提供更個人化和有效的治療。例如，Nevro 公司於 2024 年 9 月推出了 HFX AdaptivAI，這是一款由人工智慧驅動的脊髓刺激 (SCS) 系統。同樣，雅培公司於 2022 年 12 月獲得了 FDA 對其 Eterna™ SCS 系統的核准，這是目前最小的可植入式、可充電的 SCS 系統，用於治療慢性疼痛。該系統採用專有的低劑量 BurstDR™ 刺激技術，與傳統 SCS 相比，疼痛緩解效果提高了 23%。此外，類風濕性關節炎，例如 SetPoint Medical 公司的 SetPoint 系統，這是第一個用於治療類風濕性關節炎的神經免疫調節設備，於 2025 年 7 月獲得 FDA核准，為病情控制不佳的患者提供了藥物以外的替代方案。

這些舉措，例如美國將九月定為“疼痛意識月”，旨在教育公眾了解早期療育的重要性以及非鴉片類鎮痛方法的可用性。這種關注的轉變是對鴉片類藥物危機的直接回應，美國國立衛生美國(NIH) 和美國食品藥物管理局 (FDA) 等機構正在推廣更安全的替代療法。

歐洲疼痛管理醫療設備市場趨勢

歐洲疼痛管理醫療設備市場是一個充滿活力且不斷發展的產業，其發展趨勢與北美市場既有相似之處，也有不同之處。

亞太地區疼痛管理設備

該市場是一個高成長地區，其複合年成長率超過了北美和歐洲，而這種快速擴張是由獨特的人口和經濟趨勢所驅動的。

以下列出了疼痛管理設備市場的主要企業，它們總合佔最大的市場佔有率，並引領著行業趨勢：

  • Abbott Laboratories
  • Smith's Medical
  • B. Braun SE
  • Baxter International
  • Boston Scientific Corp.
  • Avanos Medical, Inc.
  • Medtronic
  • Nevro Corp.
  • ICU Medical, Inc.
  • Omron Corporation
  • Stimwave LLC
  • Nipro
  • O&M Halyard
  • EndoStim Inc.
  • Nalu Medical, Inc.
  • Micrel Medical Devices SA
  • DyAnsys, Inc.
  • NanoVibronix, Inc.
  • Zynex Inc.
  • 其他

疼痛管理設備市場的競爭格局呈現中等集中度，少數幾家大型跨國公司主導高價值的神經刺激領域。美敦力、波士頓科學和雅培等公司是主要參與企業，它們憑藉強大的研發能力、可靠的臨床證據和完善的全球分銷網路，維持著顯著的市場佔有率，尤其是在脊髓刺激設備（SCS）等植入式設備領域。然而，隨著Nevro和Saluda Medical等規模較小、更具創新精神的新興企業不斷推出射頻和封閉回路型刺激系統等顛覆性技術，這種格局正在改變。這些新參與企業正在推動創新，專注於特定區隔市場，並提供更個人化、先進的解決方案，挑戰大型企業的統治地位。非侵入性和非處方（OTC）領域則更為分散，OMRON和Zynex等公司憑藉種類繁多的攜帶式、方便用戶使用型設備展開競爭。這反映出居家照護和遠距照護的趨勢，正在重塑整個市場的競爭格局。

  • 2025年8月，用於治療三叉神經痛的NeuroOne OneRF™射頻消融系統獲得FDA核准。預計2025年秋季上市。
  • 2025年5月，商業化階段的生物電子技術公司electroCore, Inc.完成了與NeuroMetrix, Inc.的合併，從而確立了其在非侵入式健康和保健解決方案領域多元化領先地位。 NeuroMetrix, Inc.的Quell®纖維肌痛解決方案的加入，擴展了electroCore, Inc.的生物電子療法產品組合，增強了其在退伍軍人事務部（VA）醫院系統中的地位，並顯著擴大了其在慢性疼痛和健康管理領域的潛在市場。
  • 2025 年 4 月，主要企業Globus Medical, Inc. 宣布完成對 Nevro Corp. 的收購，Nevro Corp. 是一家全球醫療設備創新者，專注於為慢性疼痛管理提供創新解決方案。

疼痛管理設備市場區隔

  • 疼痛管理設備（按設備類型分類）
  • 電刺激設備
  • 神經刺激設備
  • 脊髓刺激設備
  • 深層腦部刺激器
  • 薦骨神經刺激器
  • 其他
  • 經皮電刺激（TENS）
  • 其他
  • 鎮痛輸注泵
  • 鞘內輸注泵
  • 體外輸液泵
  • 消融裝置
  • 射頻消融裝置
  • 冷凍消融裝置
  • 其他
  • 疼痛管理設備應用
  • 肌肉骨骼疼痛
  • 癌症疼痛
  • 神經病變疼痛
  • 其他
  • 疼痛管理設備的終端用戶趨勢
  • 醫院
  • 專科診所
  • 復健中心/物理治療中心
  • 居家醫療
  • 其他
  • 按地區分類的疼痛管理設備使用情況
  • 北美疼痛管理設備市場
  • 美國疼痛管理設備市場
  • 加拿大疼痛管理設備市場
  • 墨西哥疼痛管理設備市場
  • 歐洲疼痛管理設備市場
  • 英國疼痛管理設備市場
  • 德國疼痛管理設備市場
  • 法國疼痛管理設備市場
  • 義大利疼痛管理設備市場
  • 西班牙疼痛管理設備市場
  • 其他歐洲疼痛管理設備市場
  • 亞太地區疼痛管理設備市場
  • 中國疼痛管理設備市場
  • 日本疼痛管理設備市場
  • 印度疼痛管理設備市場
  • 澳洲疼痛管理設備市場
  • 韓國疼痛管理設備市場
  • 亞太地區其他疼痛管理設備市場
  • 世界其他地區疼痛管理設備市場
  • 南美洲疼痛管理設備市場
  • 中東疼痛管理設備市場
  • 非洲疼痛管理設備市場

利用人工智慧進行影響分析

人工智慧驅動的創新有望徹底改變疼痛管理設備市場，使其從被動應對轉變為主動預防、個人化的護理模式。這項轉變主要得益於Nevro和美敦力等公司所開發的閉合迴路系統。這些系統利用人工智慧分析即時患者數據，並自動調整神經刺激療法，實現更有效、更穩定的疼痛緩解。此外，人工智慧透過分析醫學影像和穿戴式感測器數據來增強診斷能力，更準確地識別疼痛原因並預測未來疼痛發作，從而實現及時干預。這項技術也推動了智慧穿戴裝置的興起，使得遠端患者監測和家庭護理中的個人化治療成為可能，這一趨勢正迅速發展。此外，人工智慧有望透過臉部和身體變異性分析客觀量化疼痛，從而解決醫療保健領域的不平等問題，提供比傳統主觀方法更客觀的評估。儘管在檢驗和資料隱私方面仍存在挑戰，但人工智慧的角色不僅僅是一項功能，而是塑造疼痛管理設備未來發展的基礎組成部分，使其在慢性疼痛管理方面更加智慧和高效。

目錄

第1章 疼痛管理設備市場報告概述

  • 調查範圍
  • 市場區隔
  • 市場假設

2. 疼痛管理設備市場摘要整理

  • 市場概覽

第3章：疼痛管理設備市場關鍵因素分析

  • 市場促進因素
    • 慢性病及相關疾病盛行率不斷上升
    • 從鴉片類藥物鎮痛過渡到其他鎮痛方式
    • 技術和創新方面的進步
    • 有利的監管和報銷環境
  • 市場阻礙與課題
    • 設備和手術高成本
    • 嚴格而複雜的法規結構
    • 植入醫療器材的風險和併發症
  • 市場機遇
    • 「智慧」與非侵入式科技的興起

第4章 影響分析

  • 人工智慧驅動的創新和應用
  • 美國關稅的影響分析

第5章 監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章 疼痛管理設備市場：波特五力分析

第7章 疼痛管理設備市場評估

  • 依設備類型
    • 電刺激設備
    • 止痛藥輸注泵
    • 消融裝置
    • 其他
  • 透過使用
    • 肌肉骨骼疼痛
    • 癌症疼痛
    • 神經病變疼痛
  • 最終用戶
    • 醫院
    • 專科診所
    • 復健中心/物理治療中心
    • 居家醫療設備
  • 地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 競爭情勢

第9章Start-Ups資金籌措與投資趨勢

10. 疼痛管理設備市場中的公司與產品概況

  • Abbott Laboratories
  • Smith's Medical
  • B. Braun SE
  • Baxter International
  • Boston Scientific Corp.
  • Avanos Medical, Inc.
  • Medtronic
  • Nevro Corp.
  • Abbott
  • ICU Medical, Inc.
  • Omron Corporation
  • Stimwave LLC
  • Nipro
  • O&M Halyard
  • EndoStim Inc.
  • Nalu Medical, Inc.
  • Micrel Medical Devices SA
  • DyAnsys, Inc.
  • NanoVibronix, Inc.
  • Zynex Inc.

第11章：KOL視角

第12章計劃方法

第13章：關於 DelveInsight

第14章 免責聲明和聯絡我們

Product Code: DIMDCL0060

Pain Management Devices Market Summary

  • The global pain management devices market is expected to increase from USD 5,277.30 million in 2024 to USD 9,350.72 million by 2032, reflecting strong and sustained growth.
  • The global pain management devices market is growing at a CAGR of 7.53% during the forecast period from 2025 to 2032.
  • The global pain management devices market is set to grow rapidly from 2025 to 2032, driven by the rising prevalence of chronic pain, frequent product launches, and increasing awareness of pain management solutions. Growing demand for minimally invasive devices and supportive awareness campaigns are boosting adoption, creating strong opportunities for innovation and improved patient outcomes.
  • The leading companies operating in the pain management devices market include Abbott Laboratories, Smith's Medical, B. Braun SE, Baxter International, Boston Scientific Corp., Avanos Medical, Inc., Medtronic, Nevro Corp., ICU Medical, Inc., Omron Corporation, Stimwave LLC, Nipro, O&M Halyard, EndoStim Inc., Nalu Medical, Inc., Micrel Medical Devices SA, DyAnsys, Inc., NanoVibronix, Inc., Zynex Inc., and Others.
  • North America is expected to remain a dominant force in the pain management devices market, driven by the high burden of chronic pain, increasing awareness initiatives, supportive government programs, and continuous product innovations with frequent FDA approvals.
  • In the device type segment of the pain management devices market, the Neurostimulation devices category is estimated to account for the largest market share in 2024.

Factors Contributing to the Growth of the Pain Management Devices Market

  • The Growing Prevalence of Chronic Pain and Related Conditions Leading to a Surge in the Pain Management Devices Market: This is not a single, isolated factor but rather a complex issue stemming from several interconnected demographic and health trends.
  • Aging Population: As life expectancy increases worldwide, the proportion of the population aged 65 and over is growing. This demographic shift is directly linked to a higher prevalence of chronic pain. Older adults are more susceptible to age-related conditions that cause persistent pain, such as:
  • Osteoarthritis: A degenerative joint disease that becomes more common with age.
  • Musculoskeletal disorders: Including back pain, which is one of the leading causes of disability globally.
  • Neuropathic pain: Nerve-related pain that can result from age-related nerve damage.
  • Chronic Diseases: The rising global burden of chronic diseases like diabetes and cancer contributes to a higher prevalence of neuropathic pain and other forms of pain that require long-term management. For instance:
  • Diabetes: Can lead to a type of nerve damage called diabetic neuropathy, which causes chronic pain, tingling, and numbness.
  • Cancer: Both the disease itself and its treatments (e.g., chemotherapy, radiation) can cause severe and persistent pain.
  • Obesity: Places added stress on joints and the skeletal system, leading to a higher incidence of back, knee, and hip pain.
  • Lifestyle Changes: Sedentary lifestyles and occupational factors are leading to a rise in conditions like back pain and other musculoskeletal issues, fueling the demand for non-pharmacological pain relief.
  • Sedentary Lifestyles: Long hours spent sitting at desks or in front of screens can lead to poor posture and chronic back and neck pain.
  • Repetitive Strain Injuries: Certain occupations involve repetitive motions that can lead to conditions like carpal tunnel syndrome or other forms of tendonitis.
  • The Shift Away from Opioid-Based Pain Management: It is a critical factor driving the growth of the pain management devices market, and it is a direct response to a global public health crisis.
  • The Opioid Crisis and Its Impact: The global opioid crisis has highlighted the dangers of addiction, misuse, and abuse associated with traditional pain medications. This has prompted healthcare providers, patients, and regulators to actively seek safer, non-addictive alternatives. Also, the over-prescription of opioid painkillers for both acute and chronic pain led to a public health crisis in many countries, most notably the United States. Key issues include:
  • Addiction and Abuse: Many individuals who were prescribed opioids for pain management developed a dependence or addiction, which can lead to substance use disorder and, in some cases, a transition to more dangerous illicit opioids like heroin or fentanyl.
  • Overdose Deaths: A staggering number of overdose deaths have been attributed to both prescription and illicit opioids, making it a leading cause of unintentional injury deaths.
  • Public and Professional Concern: The scale of the crisis has generated widespread concern among the general public, healthcare providers, and policymakers, leading to a strong push for non-pharmacological alternatives.
  • Reduced Side Effects: Pain management devices, particularly non-invasive ones, offer a way to alleviate pain without the systemic side effects (e.g., drowsiness, nausea, constipation) of oral pain medications.
  • The Rise of Multimodal Pain Management: The shift away from opioids has accelerated the adoption of a multimodal approach to pain management. This involves using a combination of different therapies to achieve optimal pain relief. Pain management devices fit perfectly into this model, as they can be used alongside non-opioid medications (e.g., NSAIDs), physical therapy, and other interventions. For example, a patient recovering from surgery might use a TENS unit to manage their post-operative pain, reducing their need for oral opioids.

In summary, the opioid crisis has acted as a powerful catalyst, forcing a fundamental change in the way pain is treated. This has created a significant market opportunity for pain management devices, which are positioned as a safer, non-addictive, and effective alternative to traditional drug-based pain relief.

  • Technological Advancements and Innovation:
  • Neuromodulation Technologies: Breakthroughs in neurostimulation, such as closed-loop systems and miniaturized implantable devices, are making these treatments more effective, personalized, and less invasive.
  • Smart and Wearable Devices: The development of portable, user-friendly, and wearable devices (like TENS units) allows for convenient, at-home pain management, reducing the need for frequent clinical visits.
  • Integration with Digital Health: The incorporation of artificial intelligence (AI), remote monitoring, and digital health platforms allows for more precise and data-driven pain management, improving patient outcomes.

Pain Management Devices Market Report Segmentation

This pain management devices market report offers a comprehensive overview of the global pain management devices market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Device Type {Electrical Stimulation Devices [Neurostimulation Devices, (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, and Others), Transcutaneous Electrical Nerve Stimulation (TENS), and Others], Analgesic Infusion Pumps (Intrathecal Infusion Pumps, External Infusion Pumps), Ablation Devices (Radiofrequency Ablation Devices, Cryoablation Devices), and Others}, Application (Musculoskeletal Pain, Cancer Pain, Neuropathic Pain, and Others), End-Users (Hospitals, Specialty Clinics, Rehabilitation Centers/Physiotherapy Centers, Homecare Settings, and Others), and Geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing pain management devices market.

Pain management devices are a category of medical equipment designed to alleviate pain without the need for or as an alternative to oral medications, particularly opioids. They work by either stimulating the body's natural pain-relieving mechanisms or by blocking pain signals from reaching the brain. These devices are used to manage a wide range of chronic and acute pain conditions, including those related to musculoskeletal disorders, neuropathic pain, and post-surgical recovery.

The growing prevalence of chronic pain, coupled with an increasing number of product launches and rising awareness of pain management solutions, is expected to drive significant growth in the global pain management devices market. As patient demand for effective and minimally invasive treatments rises, leading companies are introducing advanced devices that expand treatment options while intensifying market competition and innovation. Moreover, awareness campaigns and patient advocacy are fostering greater acceptance and adoption of these technologies worldwide. Collectively, these factors are creating a favorable environment for market expansion, promising improved patient outcomes and enhanced quality of life for individuals suffering from chronic pain during the forecast period of 2025 to 2032.

What are the latest Pain Management Devices Market Dynamics and Trends?

The global pain management devices market is experiencing robust growth, driven by the rising prevalence of chronic pain conditions across oncology, musculoskeletal, and neurological disorders. A significant contributor is cancer-related pain, particularly neuropathic cancer pain (NCP), which often remains inadequately managed with conventional therapies. With cancer cases surging worldwide, including breast, lung, and prostate cancers, the demand for advanced pain management solutions continues to climb. According to DelveInsight (2024), there were approximately 102,000 incident cases of triple-negative breast cancer (TNBC) in the 7MM in 2023. Global breast cancer incidence, which reached 2.3 million cases in 2022, is projected to escalate to 3.36 million by 2045. This expanding patient pool underscores the critical role of innovative devices in delivering effective pain relief and improving quality of life.

The growing burden of musculoskeletal diseases is another major growth driver. According to the Global Burden of Disease (2023), nearly one billion people are projected to have osteoarthritis by 2050, with steep increases anticipated in the knee (+74.9%), hip (+78.6%), hand (+48.6%), and other joints such as the elbow and shoulder (+95.1%). This sharp rise highlights the urgent need for accessible and effective pain-relieving technologies, positioning pain management devices as indispensable in addressing the long-term impact of osteoarthritis.

Neurological conditions further amplify market demand. The Global Burden of Disease Study 2021, published in The Lancet Neurology, reported that neurological disorders affected 3.4 billion people globally, 43% of the world's population, making them the leading cause of disability and ill health. Among these, tension-type headaches (~2 billion cases) and migraines (~1.1 billion cases) remain highly prevalent. Devices such as neurostimulation systems, including those targeting occipital nerves, have proven effective in interrupting pain signals and providing relief for chronic headaches and migraines. Meanwhile, the diabetic neuropathy population has more than tripled since 1990, reaching 206 million in 2021, fueling further adoption of devices designed to alleviate nerve-related pain.

Collectively, the rising incidence of cancer, osteoarthritis, and neurological conditions, coupled with continuous product innovations by leading players, is creating a highly favorable environment for the expansion of the global pain management devices market.

However, the growth of the global pain management devices market is significantly hampered by three main restraints: the high cost of devices and procedures, a stringent and complex regulatory framework, and the inherent risks and complications of implantable devices. The high cost is a major barrier, as advanced devices like neurostimulators are expensive to produce, and their associated surgical costs are prohibitive for many patients and healthcare systems, often compounded by inconsistent insurance reimbursement. Furthermore, the regulatory environment is challenging; a lengthy and costly approval process for high-risk devices stifles innovation and slows the entry of new technologies into the market. Finally, patient and physician adoption is limited by concerns over surgical risks and the potential for device-specific complications, such as lead migration or a loss of efficacy over time, which may necessitate further, costly surgeries. These combined factors create significant hurdles that restrain the market's full potential despite the rising need for non-opioid pain management solutions.

Pain Management Devices Market Segment Analysis

Pain Management Devices Market by Device Type {Electrical Stimulation Devices [Neurostimulation Devices, (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, and Others), Transcutaneous Electrical Nerve Stimulation (TENS), and Others], Analgesic Infusion Pumps (Intrathecal Infusion Pumps, External Infusion Pumps), Ablation Devices (Radiofrequency Ablation Devices, Cryoablation Devices), and Others}, Application (Musculoskeletal Pain, Cancer Pain, Neuropathic Pain, and Others), End-Users (Hospitals, Specialty Clinics, Rehabilitation Centers/Physiotherapy Centers, Homecare Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

By Device Type: Neurostimulation Device Category Dominates the Market

Within the neurostimulation devices segment, which leads the overall pain management devices market with a share of about 55%, the spinal cord stimulator (SCS) category accounted for more than 45% of the neurostimulation market in 2024. This dominance is primarily attributed to the widespread clinical adoption of SCS as a standard treatment option for chronic and refractory pain.

The market for neurostimulation devices is experiencing substantial growth, driven by a combination of factors. The rising global prevalence of chronic diseases, such as chronic pain. This increased disease burden has created a greater demand for effective, long-term therapeutic options. Furthermore, significant technological advancements have made these devices more effective and user-friendly. Innovations such as smaller, rechargeable implants, "closed-loop" systems that respond to neural activity in real time, and the development of non-invasive options like Transcranial Magnetic Stimulation (TMS) are expanding their adoption. Additionally, a more favorable regulatory environment and improved reimbursement policies are making these treatments more accessible to patients. This includes regulatory bodies approving a wider range of neurostimulators for new applications and insurers providing better coverage. Finally, the aging global population, which has a higher incidence of age-related neurological disorders and chronic pain, further contributes to the market's strong growth trajectory.

According to the World Health Organization (2023), there were approximately 619 million cases of lower back pain (LBP), a figure expected to climb to 843 million by 2050. In parallel, the European Pain Federation (2023) reported that around 740 million people globally experience at least one episode of severe pain during their lifetime, with nearly 20% developing chronic pain lasting more than three months. This growing burden of chronic pain highlights the urgent need for effective and sustainable pain management solutions.

Spinal cord stimulators (SCS) have gained traction as they provide a minimally invasive, drug-free, and reversible therapy option. By delivering targeted electrical impulses to the spinal cord, these devices block pain signals before they reach the brain, significantly improving patients' quality of life. The rising incidence of chronic pain disorders is, therefore, expected to be a major driver of SCS adoption worldwide.

Furthermore, findings published by the NIH (2023) revealed that Failed Back Surgery Syndrome (FBSS) affects 10-40% of patients following spinal surgeries. With the growing volume of spinal procedures for conditions such as herniated discs, spinal stenosis, and degenerative disc disease, the prevalence of FBSS continues to rise. Since repeated surgeries carry higher risks and often fail to deliver lasting pain relief, spinal cord stimulators are increasingly being recognized as an effective alternative. Their ability to reduce dependency on opioids, improve functional outcomes, and lower long-term healthcare costs makes them a preferred treatment choice, particularly for patients with FBSS and chronic neuropathic pain.

Emerging regulatory approvals are catalyzing market growth by enabling easier access to advanced SCS technologies: In April 2024, Medtronic gained FDA approval for Inceptiv(TM), the first closed-loop SCS system to automatically adjust stimulation using real-time biological feedback (evoked compound action potentials, or ECAPs), maintaining optimal therapy even during daily movement. It is also the only FDA-approved closed-loop system offering full-body 3T MRI access with no restrictions, and is touted as the smallest and thinnest fully implantable SCS device.

In April 2023, Biotronik received FDA approval for its Prospera SCS System, featuring RESONANCE, the first multiphase stimulation paradigm, and Embrace One, a patient-centric care model offering automatic, objective, daily remote monitoring, ongoing management, and support. The system also includes HomeStream remote management, rechargeable implants, and full-body MRI compatibility.

Each of these advancements highlights the trajectory of the SCS market, shifting from traditional, fixed-output devices requiring routine in-clinic adjustments to intelligent, adaptive systems that emphasize remote care, personalization, and workflow efficiency.

Pain Management Devices Market Regional Analysis

North America Pain Management Devices Market Trends

North America, led by the U.S., accounted for a dominant ~45% share of the global pain management devices market in 2024. The North American pain management devices market is experiencing robust growth, driven by a trifecta of factors: the increasing burden of chronic pain, a surge in recent product innovations and approvals, and supportive government initiatives.

A key driver is the alarming prevalence of chronic pain across the region. According to recent data from the Centers for Disease Control and Prevention (CDC), in 2021, an estimated 51.6 million U.S. adults, or 20.9% of the population, were living with chronic pain. A significant subset of this group, 17.1 million individuals, experienced high-impact chronic pain that severely limits daily activities. This is further compounded by the aging demographic, which is more susceptible to chronic conditions like arthritis. The CDC highlights that in 2022, the age-adjusted prevalence of diagnosed arthritis in the U.S. was 18.9%, with a sharp increase to 53.9% in adults aged 75 and older. This widespread prevalence of chronic, debilitating pain creates an immense and sustained demand for effective, long-term pain management solutions beyond traditional pharmaceuticals.

The market's growth is also being fueled by a flurry of recent product approvals and launches that are transforming the treatment landscape. These new devices are often minimally invasive, incorporating advanced technologies like artificial intelligence (AI) and closed-loop systems to offer more personalized and effective therapy. For instance, in September 2024, Nevro launched HFX AdaptivAI, an AI-driven spinal cord stimulation (SCS) system that uses real-time patient feedback to personalize therapy. Similarly, in December 2022, Abbott received FDA approval for its Eterna(TM) SCS system, the smallest implantable, rechargeable SCS available for chronic pain treatment. It uses proprietary low-dose BurstDR(TM) stimulation, which has shown a 23% greater reduction in pain compared to traditional SCS. Furthermore, recent innovations are also targeting specific conditions, such as SetPoint Medical's SetPoint System, which received FDA approval in July 2025 as the first neuroimmune modulation device for rheumatoid arthritis, offering a non-pharmaceutical alternative for patients with inadequately managed disease.

Finally, increasing government initiatives and public awareness campaigns are further propelling market growth. These efforts, such as the designation of September as Pain Awareness Month in the U.S., aim to educate the public on the importance of early intervention and the availability of non-opioid pain relief methods. This shift in focus is a direct response to the opioid crisis, with institutions like the National Institutes of Health (NIH) and the FDA promoting safer alternatives. The robust regulatory framework and favorable reimbursement policies for advanced procedures also incentivize the adoption of these innovative devices, making them more accessible to a wider patient population.

Europe Pain Management Devices Market Trends

The pain management devices market in Europe is a dynamic and growing sector, driven by trends that are both similar to and distinct from those in North America. The market is projected to grow at a significant compound annual growth rate (CAGR) in the coming years, with key drivers and trends shaping its trajectory.

Asia-Pacific Pain Management Devices Market Trends

The Asia-Pacific pain management devices market is a high-growth region, poised to outpace North America and Europe in terms of compound annual growth rate (CAGR). This rapid expansion is driven by a unique set of demographic and economic trends.

Who are the major players in the Pain Management Devices Market?

The following are the leading companies in the pain management devices market. These companies collectively hold the largest market share and dictate industry trends.

  • Abbott Laboratories
  • Smith's Medical
  • B. Braun SE
  • Baxter International
  • Boston Scientific Corp.
  • Avanos Medical, Inc.
  • Medtronic
  • Nevro Corp.
  • ICU Medical, Inc.
  • Omron Corporation
  • Stimwave LLC
  • Nipro
  • O&M Halyard
  • EndoStim Inc.
  • Nalu Medical, Inc.
  • Micrel Medical Devices SA
  • DyAnsys, Inc.
  • NanoVibronix, Inc.
  • Zynex Inc.
  • Others

How is the competitive landscape shaping the pain management devices market?

The competitive landscape of the pain management devices market is defined by a moderate degree of concentration, with a handful of major multinational corporations dominating the high-value, neurostimulation segment. Companies like Medtronic, Boston Scientific, and Abbott Laboratories are the key players, leveraging their extensive R&D capabilities, strong clinical evidence, and established global distribution networks to maintain a significant market share, particularly in implantable devices like spinal cord stimulators (SCS). However, this dynamic is evolving as the market is also populated by a growing number of smaller, innovative players and startups, such as Nevro and Saluda Medical, which are introducing disruptive technologies like high-frequency and closed-loop stimulation systems. These new entrants are driving innovation and challenging the dominance of the larger firms by focusing on specific niches and offering advanced, more personalized solutions. The non-invasive and over-the-counter (OTC) segments are more fragmented, with companies like Omron and Zynex competing with a broad range of portable, user-friendly devices, reflecting a shift towards at-home and remote care that is reshaping competitive strategies across the entire market.

Recent Developmental Activities in the Pain Management Devices Market

  • In August 2025, the FDA cleared NeuroOne OneRF(TM) Radiofrequency Ablation System targeting trigeminal neuralgia via RF ablation, a minimally invasive alternative to traditional interventions. Planned commercial launch in fall 2025.
  • In May 2025, electroCore, Inc., a commercial-stage bioelectronic technology company, completed its merger with NeuroMetrix, Inc., positioning itself as a diversified leader in non-invasive health and wellness solutions. The addition of NeuroMetrix's Quell(R) Fibromyalgia Solution broadens electroCore's portfolio of bioelectronic therapies, enhances its presence within the VA Hospital System, and significantly expands its addressable market in chronic pain and wellness management.
  • In April 2025, Globus Medical, Inc., a leading musculoskeletal technology company, announced the completion of its previously disclosed acquisition of Nevro Corp., a global innovator in medical devices focused on delivering transformative solutions for chronic pain management.

Pain Management Devices Market Segmentation

  • Pain Management Devices by Device Type Exposure
  • Electrical Stimulation Devices
  • Neurostimulation Devices
  • Spinal Cord Stimulators
  • Deep Brain Stimulators
  • Sacral Nerve Stimulators
  • Others
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Others
  • Analgesic Infusion Pumps
  • Intrathecal Infusion Pumps
  • External Infusion Pumps
  • Ablation Devices
  • Radiofrequency Ablation Devices
  • Cryoablation Devices
  • Others
  • Pain Management Devices Application Exposure
  • Musculoskeletal Pain
  • Cancer Pain
  • Neuropathic Pain
  • Others
  • Pain Management Devices End-Users Exposure
  • Hospitals
  • Specialty Clinics
  • Rehabilitation Centers / Physiotherapy Centers
  • Homecare Settings
  • Others
  • Pain Management Devices Geography Exposure
  • North America Pain Management Devices Market
  • United States Pain Management Devices Market
  • Canada Pain Management Devices Market
  • Mexico Pain Management Devices Market
  • Europe Pain Management Devices Market
  • United Kingdom Pain Management Devices Market
  • Germany Pain Management Devices Market
  • France Pain Management Devices Market
  • Italy Pain Management Devices Market
  • Spain Pain Management Devices Market
  • Rest of Europe Pain Management Devices Market
  • Asia-Pacific Pain Management Devices Market
  • China Pain Management Devices Market
  • Japan Pain Management Devices Market
  • India Pain Management Devices Market
  • Australia Pain Management Devices Market
  • South Korea Pain Management Devices Market
  • Rest of Asia-Pacific Pain Management Devices Market
  • Rest of the World Pain Management Devices Market
  • South America Pain Management Devices Market
  • Middle East Pain Management Devices Market
  • Africa Pain Management Devices Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations are set to revolutionize the pain management devices market by transitioning it from a reactive to a proactive and personalized model of care. This transformation is primarily driven by the development of closed-loop systems, such as those from Nevro and Medtronic, which use AI to analyze real-time patient data and automatically adjust neurostimulation therapy for more effective and consistent pain relief. Furthermore, AI is enhancing diagnostics by analyzing medical images and wearable sensor data to more accurately identify the source of pain and predict future flare-ups, allowing for timely intervention. The technology also supports the rise of smart and wearable devices, enabling remote patient monitoring and personalized therapy in home care settings, a trend that is gaining significant traction. Additionally, AI holds promise in addressing healthcare disparities by objectively quantifying pain through the analysis of facial expressions and body movements, offering a more unbiased assessment than traditional subjective methods. Despite challenges related to validation and data privacy, AI's role is not merely as a feature but as a fundamental component that will shape the future of pain management devices, making them more intelligent and effective in combating chronic pain.

U.S. Tariff Impact Analysis on the Pain Management Devices Market:

The U.S. government's tariffs have had a complex and disruptive impact on the pain management devices market, primarily by raising costs for manufacturers and consumers. Tariffs on imports from key suppliers, notably China and the EU, have forced companies to either absorb costs, thus reducing profit margins, or pass them on to healthcare providers, potentially limiting patient access to care. This has also exposed the fragility of global supply chains, prompting a strategic shift toward diversification, with companies relocating manufacturing to countries with more favorable trade agreements or re-shoring production to the U.S. Furthermore, while tariffs may offer a temporary advantage to some domestic producers, they also create a climate of uncertainty that can deter foreign investment and lead to a re-evaluation of research and development budgets, ultimately impacting the pace of innovation within the market.

How This Analysis Helps Clients

  • Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
  • Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
  • Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
  • Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the pain management devices market report study

  • Market size analysis for the current pain management devices market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the pain management devices market.
  • Various opportunities available for the other competitors in the pain management devices market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current pain management devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for the pain management devices market growth in the future?

Frequently Asked Questions for the Pain Management Devices Market

1. What is the growth rate of the pain management devices market?

  • The pain management devices market is estimated to grow at a CAGR of 7.53% during the forecast period from 2025 to 2032.

2. What is the market for pain management devices?

3. The pain management devices market was valued at USD 5,277.30 million in 2024, and is expected to reach USD 9,350.72 million by 2032.

4. Which region has the highest share in the pain management devices market?

  • North America is expected to remain a dominant force in the pain management devices market, driven by the high burden of chronic pain, increasing awareness initiatives, supportive government programs, and continuous product innovations with frequent FDA approvals.

5. What are the drivers for the pain management devices market?

  • The global pain management devices market is set to grow rapidly from 2025 to 2032, driven by the rising prevalence of chronic pain, frequent product launches, and increasing awareness of pain management solutions. Growing demand for minimally invasive devices and supportive awareness campaigns are boosting adoption, creating strong opportunities for innovation and improved patient outcomes.

6. Who are the key players operating in the pain management devices market?

  • Some of the key market players operating in the pain management devices market include Abbott Laboratories, Smith's Medical, B. Braun SE, Baxter International, Boston Scientific Corp., Avanos Medical, Inc., Medtronic, Nevro Corp., Abbott, ICU Medical, Inc., Omron Corporation, Stimwave LLC, Nipro, O&M Halyard, EndoStim Inc., Nalu Medical, Inc., Micrel Medical Devices SA, DyAnsys, Inc., NanoVibronix, Inc., Zynex Inc., and Others.

Table of Contents

1. Pain Management Devices Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Pain Management Devices Market Executive Summary

  • 2.1 Market at Glance

3. Pain Management Devices Market Key Factors Analysis

  • 3.1 Pain Management Devices Market Drivers
    • 3.1.1 Rising Prevalence of Chronic and Related Conditions
    • 3.1.2 Shift Away from Opioid-Based Pain Management
    • 3.1.3 Advancements in Technology and Innovation
    • 3.1.4 Favourable Regulatory and Reimbursement Landscape
  • 3.2 Pain Management Devices Market Restraints and Challenges
    • 3.2.1 High Cost of Devices and Procedures
    • 3.2.2 Stringent and Complex Regulatory Frameworks
    • 3.2.3 Risks and Complications of Implantable Devices
  • 3.3 Pain Management Devices Market Opportunity
    • 3.3.1 Rise of "Smart" and Non-Invasive Technologies

4. Impact Analysis

  • 4.1 AI-Powered Innovations and Applications
  • 4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

  • 5.1 The United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Pain Management Devices Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Pain Management Devices Market Assessment

  • 7.1 By Device Type
    • 7.1.1 Electrical Stimulation Devices
      • 7.1.1.1 Neurostimulation Devices
      • 7.1.1.1.1 Spinal Cord Stimulators
      • 7.1.1.1.2 Deep Brain Stimulators
      • 7.1.1.1.3 Sacral Nerve Stimulators
      • 7.1.1.1.4 Others
      • 7.1.1.2 Transcutaneous Electrical Nerve Stimulation (TENS)
      • 7.1.1.3 Others
    • 7.1.2 Analgesic Infusion Pumps
      • 7.1.2.1 Intrathecal Infusion Pumps
      • 7.1.2.2 External Infusion Pumps
    • 7.1.3 Ablation Devices
      • 7.1.3.1 Radiofrequency Ablation Devices
      • 7.1.3.2 Cryoablation Devices
    • 7.1.4 Others
  • 7.2 By Application
    • 7.2.1 Musculoskeletal Pain
    • 7.2.2 Cancer Pain
    • 7.2.3 Neuropathic Pain
    • 7.2.4 Others
  • 7.3 By End-Users
    • 7.3.1 Hospitals
    • 7.3.2 Specialty Clinics
    • 7.3.3 Rehabilitation Centers / Physiotherapy Centers
    • 7.3.4 Homecare Settings
    • 7.3.5 Others
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.1.2 Canada Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.1.3 Mexico Pain Management Devices Market Size in USD million (2022-2032)
    • 7.4.2 Europe
      • 7.4.2.1 France Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.2.2 Germany Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.2.3 United Kingdom Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.2.4 Italy Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.2.5 Spain Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.2.6 Rest of Europe Pain Management Devices Market Size in USD million (2022-2032)
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.3.2 Japan Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.3.3 India Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.3.4 Australia Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.3.5 South Korea Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.3.6 Rest of Asia-Pacific Pain Management Devices Market Size in USD million (2022-2032)
    • 7.4.4 Rest of the World (RoW)
      • 7.4.4.1 Middle East Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.4.2 Africa Pain Management Devices Market Size in USD million (2022-2032)
      • 7.4.4.3 South America Pain Management Devices Market Size In USD Million (2022-2032)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Pain Management Devices Market Company and Product Profiles

  • 10.1 Abbott Laboratories
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Product Listing
    • 10.1.5 Entropy
  • 10.2 Smith's Medical
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Listing
    • 10.2.5 Entropy
  • 10.3 B. Braun SE
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Listing
    • 10.3.5 Entropy
  • 10.4 Baxter International
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Listing
    • 10.4.5 Entropy
  • 10.5 Boston Scientific Corp.
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Listing
    • 10.5.5 Entropy
  • 10.6 Avanos Medical, Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Listing
    • 10.6.5 Entropy
  • 10.7 Medtronic
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Listing
    • 10.7.5 Entropy
  • 10.8 Nevro Corp.
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Listing
    • 10.8.5 Entropy
  • 10.9 Abbott
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Listing
    • 10.9.5 Entropy
  • 10.10 ICU Medical, Inc.
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Listing
    • 10.10.5 Entropy
  • 10.11 Omron Corporation
    • 10.11.1 Company Overview
    • 10.11.2 Company Snapshot
    • 10.11.3 Financial Overview
    • 10.11.4 Product Listing
    • 10.11.5 Entropy
  • 10.12 Stimwave LLC
    • 10.12.1 Company Overview
    • 10.12.2 Company Snapshot
    • 10.12.3 Financial Overview
    • 10.12.4 Product Listing
    • 10.12.5 Entropy
  • 10.13 Nipro
    • 10.13.1 Company Overview
    • 10.13.2 Company Snapshot
    • 10.13.3 Financial Overview
    • 10.13.4 Product Listing
    • 10.13.5 Entropy
  • 10.14 O&M Halyard
    • 10.14.1 Company Overview
    • 10.14.2 Company Snapshot
    • 10.14.3 Financial Overview
    • 10.14.4 Product Listing
    • 10.14.5 Entropy
  • 10.15 EndoStim Inc.
    • 10.15.1 Company Overview
    • 10.15.2 Company Snapshot
    • 10.15.3 Financial Overview
    • 10.15.4 Product Listing
    • 10.15.5 Entropy
  • 10.16 Nalu Medical, Inc.
    • 10.16.1 Company Overview
    • 10.16.2 Company Snapshot
    • 10.16.3 Financial Overview
    • 10.16.4 Product Listing
    • 10.16.5 Entropy
  • 10.17 Micrel Medical Devices SA
    • 10.17.1 Company Overview
    • 10.17.2 Company Snapshot
    • 10.17.3 Financial Overview
    • 10.17.4 Product Listing
    • 10.17.5 Entropy
  • 10.18 DyAnsys, Inc.
    • 10.18.1 Company Overview
    • 10.18.2 Company Snapshot
    • 10.18.3 Financial Overview
    • 10.18.4 Product Listing
    • 10.18.5 Entropy
  • 10.19 NanoVibronix, Inc.
    • 10.19.1 Company Overview
    • 10.19.2 Company Snapshot
    • 10.19.3 Financial Overview
    • 10.19.4 Product Listing
    • 10.19.5 Entropy
  • 10.20 Zynex Inc.
    • 10.20.1 Company Overview
    • 10.20.2 Company Snapshot
    • 10.20.3 Financial Overview
    • 10.20.4 Product Listing
    • 10.20.5 Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us

List of Tables

  • Table 1: Pain Management Devices Market in Global (2022-2032)
  • Table 2: Pain Management Devices Market in Global by Device Type (2022-2032)
  • Table 3: Pain Management Devices Market in Global by Application (2022-2032)
  • Table 4: Pain Management Devices Market in Global by End-Users (2022-2032)
  • Table 5: Pain Management Devices Market in Global by Geography (2022-2032)
  • Table 6: Pain Management Devices Market in North America (2022-2032)
  • Table 7: Pain Management Devices Market in the United States (2022-2032)
  • Table 8: Pain Management Devices Market in Canada (2022-2032)
  • Table 9: Pain Management Devices Market in Mexico (2022-2032)
  • Table 10: Pain Management Devices Market in Europe (2022-2032)
  • Table 11: Pain Management Devices Market in France (2022-2032)
  • Table 12: Pain Management Devices Market in Germany (2022-2032)
  • Table 13: Pain Management Devices Market in United Kingdom (2022-2032)
  • Table 14: Pain Management Devices Market in Italy (2022-2032)
  • Table 15: Pain Management Devices Market in Spain (2022-2032)
  • Table 16: Pain Management Devices Market in the Rest of Europe (2022-2032)
  • Table 17: Pain Management Devices Market in Asia-Pacific (2022-2032)
  • Table 18: Pain Management Devices Market in China (2022-2032)
  • Table 19: Pain Management Devices Market in Japan (2022-2032)
  • Table 20: Pain Management Devices Market in India (2022-2032)
  • Table 21: Pain Management Devices Market in Australia (2022-2032)
  • Table 22: Pain Management Devices Market in South Korea (2022-2032)
  • Table 23: Pain Management Devices Market in Rest of Asia-Pacific (2022-2032)
  • Table 24: Pain Management Devices Market in the Rest of the World (2022-2032)
  • Table 25: Pain Management Devices Market in the Middle East (2022-2032)
  • Table 26: Pain Management Devices Market in Africa (2022-2032)
  • Table 27: Pain Management Devices Market in South America (2022-2032)
  • Table 28: Competitive Landscape
  • Table 29: Startup Funding & Investment Trends

List of Figures

  • Table 1: Pain Management Devices Market Drivers
  • Table 2: Pain Management Devices Market Restraints
  • Table 3: Pain Management Devices Market Opportunities
  • Table 4: AI-Powered Innovations in Pain Management Devices Market
  • Table 5: US Tariff Impact on Pain Management Devices Market
  • Table 6: Regulatory Analysis (US, EU, Japan, China)
  • Table 7: Porter's Five Forces Analysis
  • Table 8: Competitive Analysis
  • Table 9: Pain Management Devices Market in Global (2022-2032)
  • Table 10: Pain Management Devices Market in Global by Device Type (2022-2032)
  • Table 11: Pain Management Devices Market in Global by Application (2022-2032)
  • Table 12: Pain Management Devices Market in Global by End-Users (2022-2032)
  • Table 13: Pain Management Devices Market in Global by Geography (2022-2032)
  • Table 14: Pain Management Devices Market in North America (2022-2032)
  • Table 15: Pain Management Devices Market in the United States (2022-2032)
  • Table 16: Pain Management Devices Market in Canada (2022-2032)
  • Table 17: Pain Management Devices Market in Mexico (2022-2032)
  • Table 18: Pain Management Devices Market in Europe (2022-2032)
  • Table 19: Pain Management Devices Market in France (2022-2032)
  • Table 20: Pain Management Devices Market in Germany (2022-2032)
  • Table 21: Pain Management Devices Market in United Kingdom (2022-2032)
  • Table 22: Pain Management Devices Market in Italy (2022-2032)
  • Table 23: Pain Management Devices Market in Spain (2022-2032)
  • Table 24: Pain Management Devices Market in the Rest of Europe (2022-2032)
  • Table 25: Pain Management Devices Market in Asia-Pacific (2022-2032)
  • Table 26: Pain Management Devices Market in China (2022-2032)
  • Table 27: Pain Management Devices Market in Japan (2022-2032)
  • Table 28: Pain Management Devices Market in India (2022-2032)
  • Table 29: Pain Management Devices Market in Australia (2022-2032)
  • Table 30: Pain Management Devices Market in South Korea (2022-2032)
  • Table 31: Pain Management Devices Market in Rest of Asia-Pacific (2022-2032)
  • Table 32: Pain Management Devices Market in the Rest of the World (2022-2032)
  • Table 33: Pain Management Devices Market in the Middle East (2022-2032)
  • Table 34: Pain Management Devices Market in Africa (2022-2032)
  • Table 35: Pain Management Devices Market in South America (2022-2032)
  • Table 36: Competitive Landscape
  • Table 37: Startup Funding & Investment Trends